AbbVie joins peers in Middle East with Saudi Arabia plans

AbbVie ($ABBV) is joining the rush to the Middle East with operations in Saudi Arabia. Its deal for the Arab Company for Pharmaceutical Products (Arabio) to manufacture Humira and other drugs in the kingdom is seen as a significant advance in the country's ability to manufacture biologics. AbbVie joins Pfizer ($PFE), which is building a plant there, while Sanofi ($SNY), Merck & Co. ($MRK) and others are establishing production and distribution operations throughout the Middle East. It is a region that is seen as one the emerging markets with the most potential. Story | More

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.